Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Cardiovascular effects of incretin therapy in diabetes care.

Kim J, Samson SL.

Metab Syndr Relat Disord. 2014 Aug;12(6):303-10. doi: 10.1089/met.2014.0035. Epub 2014 May 19. Review.

2.

Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.

van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M.

Diabetes Obes Metab. 2013 Jul;15(7):593-606. doi: 10.1111/dom.12050. Epub 2013 Jan 21. Review.

PMID:
23216746
3.

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Campbell RK.

Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015. Review.

PMID:
21665040
4.

Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

Neumiller JJ.

Clin Ther. 2011 May;33(5):528-76. doi: 10.1016/j.clinthera.2011.04.024. Review.

PMID:
21665041
5.

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.

Boland CL, Degeeter M, Nuzum DS, Tzefos M.

Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Review.

PMID:
23548652
6.

[Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].

Avogaro A.

G Ital Cardiol (Rome). 2016 Apr;17(4):248-52. doi: 10.1714/2214.23894. Italian.

PMID:
27093207
7.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
8.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
9.

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.

Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X.

BMJ. 2014 Apr 15;348:g2366. doi: 10.1136/bmj.g2366. Review.

10.
11.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

PMID:
23748503
12.

Novel Therapeutic Approaches in Diabetes.

Gallwitz B.

Endocr Dev. 2016;31:43-56. doi: 10.1159/000439372. Epub 2016 Jan 19. Review.

PMID:
26824365
13.

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.

Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.

PMID:
24989141
14.

An updated review on cancer risk associated with incretin mimetics and enhancers.

Tseng CH, Lee KY, Tseng FH.

J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33(1):67-124. doi: 10.1080/10590501.2015.1003496. Review.

PMID:
25803196
15.

Incretin-based therapies in type 2 diabetes mellitus.

Chia CW, Egan JM.

J Clin Endocrinol Metab. 2008 Oct;93(10):3703-16. doi: 10.1210/jc.2007-2109. Epub 2008 Jul 15. Review.

16.
17.

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Pieters IC, Cahen DL, Diamant M, van Raalte DH.

BMJ Open. 2015 Nov 19;5(11):e009579. doi: 10.1136/bmjopen-2015-009579.

18.

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.

Drab SR.

Pharmacotherapy. 2010 Jun;30(6):609-24. doi: 10.1592/phco.30.6.609. Review.

PMID:
20500049
19.

Efficacy and safety of incretin based therapies: clinical trial data.

White J.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S30-40. doi: 10.1331/JAPhA.2009.09079. Review.

PMID:
19801363
20.

Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.

Davidson MH.

Postgrad Med. 2014 May;126(3):56-65. doi: 10.3810/pgm.2014.05.2756. Review.

PMID:
24918792

Supplemental Content

Support Center